Steroid-sparing strategies for managing immune-related adverse events <p>Although immune checkpoint inhibitors (ICI) have greatly improved outcomes in several cancer types, their use is also associated with immune-related adverse events (irAEs) that can impact any organ system and lead to significant morbidity and even mortality. Current approaches to treatment of irAEs largely rely on the use of systemic corticosteroids, which can compromise antitumor immune responses and oncologic outcomes.… Journal for ImmunoTherapy of Cancer January 16, 2026 Original source
Primary and secondary pseudo-stability and progression after atezolizumab with and without bevacizumab Background <p>Atypical tumor response patterns associated with immunotherapies pose significant challenges for assessing treatment response and clinical decision-making. We characterized the epidemiology, clinical impact, and molecular determinants of pseudo-stability/progression after atezolizumab with and without bevacizumab across several histologies.</p> Methods <p>Post hoc individual-level analysis of 2980 patients across eight randomized trials of atezolizumab in non-small cell lung cancer, urothelial carcinoma, renal… Journal for ImmunoTherapy of Cancer January 16, 2026 Original source
Integrative multiomic profiling of cfDNA methylation and EV-miRNAs identifies immunotherapy-outcome molecular subtypes in NSCLC Background <p>Patients with non-small cell lung cancer (NSCLC) exhibit heterogeneous responses to immunotherapy (IT) with high resistance rates, highlighting the need for precise biomarkers of treatment outcomes.</p> Methods <p>In a prospective cohort study, we longitudinally assessed liquid biopsy samples from patients with NSCLC undergoing IT at four distinct time points (T1 pretreatment, T2 post-second cycle, T3 6 months, and T4… Journal for ImmunoTherapy of Cancer January 16, 2026 Original source
CD300ld blockade overcomes PMN-MDSC-mediated vaccine resistance in advanced tumors Background <p>While cancer vaccines have demonstrated promising clinical potential, their therapeutic efficacy against advanced tumors remains suboptimal, highlighting the critical need to elucidate resistance mechanisms and develop targeted solutions. We previously developed a stimulator of interferon genes (STING)-activating PC7A nanovaccine that elicits strong antitumor efficacy in multiple tumor models. In this study, we systematically investigated the mechanisms mediating nanovaccine resistance… Journal for ImmunoTherapy of Cancer January 16, 2026 Original source
CAR T cells: the missing piece needed to improve outcomes for children with cancer? <p>B cell acute lymphoblastic leukemia (B-ALL) is the most common cancer of childhood. Outcomes for B-ALL have steadily improved over the last five decades, most recently due to impressive activity of chimeric antigen receptor modified T (CAR-T) cells and bispecific antibodies targeting CD19. In contrast, progress against other pediatric cancers has largely stalled. Significant academic effort is underway to expand… Journal for ImmunoTherapy of Cancer January 16, 2026 Original source
Stearoyl-CoA desaturase-1 controls the differentiation and antitumoral function of Th9 lymphocytes Background <p>Stearoyl-CoA desaturase 1 (SCD1) is a key enzyme in fatty acid (FA) metabolism that catalyzes the addition of a cis double bond to palmitic and stearic saturated FAs, producing palmitoleic and oleic monounsaturated FAs, respectively. Interleukin (IL)9-secreting CD4<sup>+</sup> T-helper lymphocytes (Th9) exert antitumoral activity in preclinical cancer models. In the present study, we evaluated the role of SCD1 in… Journal for ImmunoTherapy of Cancer January 16, 2026 Original source
Biomarkers of activity from a phase I study of cergutuzumab amunaleukin in patients with advanced solid tumors Background <p>Cergutuzumab amunaleukin (CA) is an immunocytokine comprising an anticarcinoembryonic antigen (CEA) linked to an interleukin-2 (IL-2) variant. CA does not bind to CD25 (IL-2 receptor α) and was designed to maintain the T and natural killer (NK) cell stimulatory effect, while avoiding stimulating effects on regulatory T cells (Tregs). In mouse models, CA previously demonstrated superior tumor targeting to… Journal for ImmunoTherapy of Cancer January 16, 2026 Original source
Therapeutic vaccination for glioblastoma elicited by retargeted oncolytic herpes virus Background <p>Glioblastoma is an aggressive tumor with poor prognosis and limited treatment options due to its resistance to chemotherapy and radiotherapy, high heterogeneity, and ability to evade the immune system. Nevertheless, immunotherapy and oncolytic virotherapy are emerging as promising strategies. This study aimed to evaluate the therapeutic efficacy of an engineered oncolytic Herpes Simplex Virus for glioblastoma treatment.</p> Methods <p>We… Journal for ImmunoTherapy of Cancer January 16, 2026 Original source
Heterocellular crosstalk and architecture of the pancreatic tumour microenvironment <p>Nature Reviews Cancer, Published online: 16 January 2026; <a href="https://www.nature.com/articles/s41568-025-00905-9">doi:10.1038/s41568-025-00905-9</a></p>Pancreatic ductal adenocarcinoma is defined by a fibroinflammatory microenvironment, which influences both disease progression and therapy response. In this Review, Arnold et al. outline our current understanding of the complex interplay between the stromal elements of the tumour microenvironment in pancreatic ductal adenocarcinoma and present ways we might use this knowledge… Nature Reviews Cancer January 16, 2026 Original source
Dana-Farber Researchers Create Experimental AI-based Oncologist’s Assistant <p>There are over 100 precision medicines approved for the treatment of cancer. These therapies work to shut down the cancer-driving effects of specific mutations.  Matching a patient to a medicine — the practice of precision oncology — is complex and advancing rapidly. However, there is no easy, standardized way for oncologists to stay informed of advances.  “The clinicians we engaged with said that catching up with FDA approvals is far ... <a class="read-more" href="https://blog.dana-farber.org/insight/2026/01/dana-farber-researchers-create-experimental-ai-based-oncologists-assistant/" title="Dana-Farber… Dana-Farber Cancer Institute January 15, 2026 Original source
Correction: Development of therapeutic monoclonal antibodies against DKK1 peptide-HLA-A2 complex to treat human cancers Journal for ImmunoTherapy of Cancer January 15, 2026 Original source
An Immune-privileged niche mediates immunotherapy resistance in esophageal carcinoma Background <p>Neoadjuvant immunotherapy has reshaped the treatment paradigm for esophageal squamous cell carcinoma (ESCC), yet mechanisms of resistance in non-responders remain poorly understood. Specifically, the spatial orchestration of the tumor microenvironment that limits effective antitumor immunity is not fully elucidated.</p> Methods <p>Integrating spatial transcriptomic analysis with large-scale tissue pathology, we mapped the spatial architecture of the immune landscape in immunotherapy-resistant… Journal for ImmunoTherapy of Cancer January 15, 2026 Original source
Molecular and functional characterization of the B-cell receptor in chronic lymphocytic leukemia-like monoclonal B-cell lymphocytosis <p>Leukemia, Published online: 07 January 2026; <a href="https://www.nature.com/articles/s41375-025-02797-y">doi:10.1038/s41375-025-02797-y</a></p>Molecular and functional characterization of the B-cell receptor in chronic lymphocytic leukemia-like monoclonal B-cell lymphocytosis Leukemia Journal January 14, 2026 Original source
Sequential BCR::ABL1 evaluation during dose de-escalation in peripheral blood is more predictive of TFR success than single assessment at dose de-escalation in either peripheral blood or bone marrow <p>Leukemia, Published online: 07 January 2026; <a href="https://www.nature.com/articles/s41375-025-02853-7">doi:10.1038/s41375-025-02853-7</a></p>Sequential BCR::ABL1 evaluation during dose de-escalation in peripheral blood is more predictive of TFR success than single assessment at dose de-escalation in either peripheral blood or bone marrow Leukemia Journal January 14, 2026 Original source
Olaparib sensitizes chronic lymphocytic leukemia to BTK- and BCL2-targeted therapies via PARP1-independent mitochondrial metabolic dysfunction <p>Leukemia, Published online: 07 January 2026; <a href="https://www.nature.com/articles/s41375-025-02846-6">doi:10.1038/s41375-025-02846-6</a></p>Olaparib sensitizes chronic lymphocytic leukemia to BTK- and BCL2-targeted therapies via PARP1-independent mitochondrial metabolic dysfunction Leukemia Journal January 14, 2026 Original source
Identifying targeted therapies for <i>CBFA2T3::GLIS2</i> acute myeloid leukemia <p>Leukemia, Published online: 08 January 2026; <a href="https://www.nature.com/articles/s41375-025-02845-7">doi:10.1038/s41375-025-02845-7</a></p>Identifying targeted therapies for <i>CBFA2T3::GLIS2</i> acute myeloid leukemia Leukemia Journal January 14, 2026 Original source
CHEK2 loss endows chemotherapy resistance to hematopoietic stem cells <p>Leukemia, Published online: 12 January 2026; <a href="https://www.nature.com/articles/s41375-025-02850-w">doi:10.1038/s41375-025-02850-w</a></p>CHEK2 loss endows chemotherapy resistance to hematopoietic stem cells Leukemia Journal January 14, 2026 Original source
Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat <p>Leukemia, Published online: 12 January 2026; <a href="https://www.nature.com/articles/s41375-025-02831-z">doi:10.1038/s41375-025-02831-z</a></p>Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat Leukemia Journal January 14, 2026 Original source
Modeling donor age and type trade-offs for personalized selection in allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide prophylaxis <p>Leukemia, Published online: 12 January 2026; <a href="https://www.nature.com/articles/s41375-025-02857-3">doi:10.1038/s41375-025-02857-3</a></p>Modeling donor age and type trade-offs for personalized selection in allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide prophylaxis Leukemia Journal January 14, 2026 Original source
Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX) <p>Leukemia, Published online: 12 January 2026; <a href="https://www.nature.com/articles/s41375-025-02859-1">doi:10.1038/s41375-025-02859-1</a></p>Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX) Leukemia Journal January 14, 2026 Original source